

# CITATION REPORT

List of articles citing

## Reimbursement for cancer treatment: coverage of off-label drug indications

DOI: 10.1200/jco.2006.06.8940

Journal of Clinical Oncology, 2006, 24, 3206-8.

**Source:** <https://exaly.com/paper-pdf/41176313/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	Cost of cancer care: the patient perspective. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 228-32	2.2	78
73	The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). <i>Annals of Oncology</i> , <b>2007</b> , 18, 1923-5	10.3	51
72	A one-day survey of characteristics of off-label hospital prescription of psychotropic drugs. <i>Pharmacopsychiatry</i> , <b>2007</b> , 40, 116-20	2	12
71	Current status of development of anticancer agents in Japan. <i>International Journal of Hematology</i> , <b>2008</b> , 87, 484-489	2.3	5
70	Temozolomide: applying healthcare fraud and abuse laws to oncology drugs. <i>Community Oncology</i> , <b>2008</b> , 5, 553-554		1
69	Off-label use of anticancer drugs. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 1102-7	21.7	64
68	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , <b>2009</b> , 95, 647-651	1.7	13
67	Recent developments in medicare coverage of off-label cancer therapies. <i>Journal of Oncology Practice</i> , <b>2009</b> , 5, 18-20	3.1	8
66	Pharmacists Role in Facilitating evidence-based prescribing for unlabeled use of medications. <i>American Journal of Health-System Pharmacy</i> , <b>2009</b> , 66, 1735-9	2.2	4
65	News and Notes From the 2009 Carrier Advisory Committee Meeting: Medical Necessity, Off-Label Chemotherapy, and More. <i>Journal of Oncology Practice</i> , <b>2009</b> , 5, 301-304	3.1	
64	Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. <i>Clinical Therapeutics</i> , <b>2009</b> , 31 Pt 2, 2273-89	3.5	37
63	Off-label prescribing: a call for heightened professional and government oversight. <i>Journal of Law, Medicine and Ethics</i> , <b>2009</b> , 37, 476-86, 396	1.2	87
62	Improving pharmaceutical care in oncology by pharmacoinformatics: the evolving role of informatics and the internet for drug therapy. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 1011-9	21.7	13
61	Systematic review: reliability of compendia methods for off-label oncology indications. <i>Annals of Internal Medicine</i> , <b>2009</b> , 150, 336-43	8	56
60	Speaking off label. <i>Hastings Center Report</i> , <b>2010</b> , 40, 9-10	3.3	1
59	Availability of experimental therapy outside oncology randomized clinical trials in the United States. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5067-73	2.2	12
58	Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 127-8	19.4	5

57	Mechanisms of action of commonly used drugs to treat cancer. <i>Community Oncology</i> , <b>2011</b> , 8, 357-369		5
56	Off-label drug use and promotion: balancing public health goals and commercial speech. <i>American Journal of Law and Medicine</i> , <b>2011</b> , 37, 225-57	0.5	14
55	No need for more regulation: payors and their role in balancing the cost and safety considerations of off-label prescriptions. <i>American Journal of Law and Medicine</i> , <b>2011</b> , 37, 422-43	0.5	3
54	Off-label use of anti-cancer drugs in India: to be or not to be!. <i>Journal of Cancer Research and Therapeutics</i> , <b>2011</b> , 7, 35-9	1.2	10
53	Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. <i>Health Affairs</i> , <b>2011</b> , 30, 1375-81	7	44
52	Providers' payment and delivery system reforms hold both threats and opportunities for the drug and device industries. <i>Health Affairs</i> , <b>2012</b> , 31, 2059-67	7	3
51	International variability in the reimbursement of cancer drugs by publically funded drug programs. <i>Current Oncology</i> , <b>2012</b> , 19, e165-76	2.8	60
50	Conflict of interest disclosure in off-label oncology clinical trials. <i>Journal of Oncology Practice</i> , <b>2012</b> , 8, 298-302	3.1	3
49	When hope hinders science and patient-centered care. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4283-4	2.2	5
48	Influence of pharmacy benefit practices on off-label dispensing of drugs in the United States. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 91, 943-5	6.1	5
47	Off-label use of oncology drugs: the need for more data and then some. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 584-6	2.2	29
46	How do initial signals of quality influence the diffusion of new medical products? The case of new cancer drug treatments. <i>Advances in Health Economics and Health Services Research</i> , <b>2012</b> , 23, 123-48		3
45	Unsupported off-label chemotherapy in metastatic colon cancer. <i>BMC Health Services Research</i> , <b>2012</b> , 12, 481	2.9	6
44	Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. <i>International Journal of Risk and Safety in Medicine</i> , <b>2012</b> , 24, 137-46	1.6	7
43	A multicenter prospective observational study of the conformity of temozolomide prescriptions in France. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 828-34	2.6	2
42	Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 505-12	2.8	20
41	Respiratory Regulation - Clinical Advances. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> ,	3.6	2
40	Rooting out institutional corruption to manage inappropriate off-label drug use. <i>Journal of Law, Medicine and Ethics</i> , <b>2013</b> , 41, 654-64	1.2	18

39	Pharmacotherapy for sarcoidosis: an example of an off-label procedure. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> , 755, 251-6	3.6	3
38	Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1134-9	2.2	91
37	Off-label prescribing in palliative care - a cross-sectional national survey of palliative medicine doctors. <i>Palliative Medicine</i> , <b>2013</b> , 27, 320-8	5.5	11
36	References. <b>2014</b> , 175-189		
35	Off-Label Use of Immunosuppressive Agents in Solid Organ Transplantation. <b>2014</b> , 1233-1241		
34	Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 719-25	2.8	20
33	Off-label use of cancer therapies in women diagnosed with breast cancer in the United States. <i>SpringerPlus</i> , <b>2015</b> , 4, 209		8
32	Cancer genomics: the challenge of drug accessibility. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 250-7	4.2	11
31	The diffusion of docetaxel in patients with metastatic prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	12
30	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1791-8 <sup>10.3</sup>		58
29	Patent Foramen Ovale. <b>2015</b> ,		
28	A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2016</b> , 23, 741-9	8.6	11
27	Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 57-65	7.3	14
26	Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. <i>BMC Medicine</i> , <b>2016</b> , 14, 17	11.4	27
25	Off-label drug use in oncology: a systematic review of literature. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2017</b> , 42, 251-258	2.2	59
24	First Amendment Protection of Evidence-Based Promotion of Prescription Drugs: A Study of Published Clinical Evidence Supporting Off-Label Promotion in the USA. <i>Pharmaceutical Medicine</i> , <b>2017</b> , 31, 309-315	2.3	0
23	Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. <i>Journal of Clinical Epidemiology</i> , <b>2018</b> , 94, 35-45	5.7	9
22	Drug repositioning: current approaches and their implications in the precision medicine era. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2018</b> , 3, 49-61	1.6	33

21	Investigating the landscape of US orphan product approvals. <i>Orphanet Journal of Rare Diseases</i> , <b>2018</b> , 13, 183	4.2	20
20	Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2018</b> , 52, 771-777	1.2	5
19	The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1210	5.6	8
18	The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from Massachusetts. <i>Journal of Law, Medicine and Ethics</i> , <b>2020</b> , 48, 538-551	1.2	1
17	Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e416-e425	2.3	5
16	Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States. <i>International Journal of Cancer</i> , <b>2022</b> , 150, 482-490	7.5	1
15	Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , e75-80	7.1	16
14	Oncologist Perspectives on Rare Cancer Care: A Nationwide Survey. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 591-9	5.2	5
13	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 754390	5.6	0
12	Off-Label Drugs in Pediatric Perioperative Medicine. <b>2009</b> , 19-27		
11	[Off-label therapies in oncology]. <i>Orvosi Hetilap</i> , <b>2009</b> , 150, 363-72	0.8	
10	The Evolving Role of Pharmacoinformatics in Targeting Drug-Related Problems in Clinical Oncology Practice. <i>Advances in Bioinformatics and Biomedical Engineering Book Series</i> , <b>2012</b> , 130-177	0.4	
9	The Many Aspects of Off-Label Prescribing in Oncology. <i>Journal of Cancer Research Updates</i> ,	1	
8	Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value. <i>SSRN Electronic Journal</i> ,	1	1
7	Challenges in Obtaining Effective Access to Prescribed Drugs and Protection Against Financial Disruption: Addressing Barriers to Cancer Care in Ontario. <i>SSRN Electronic Journal</i> ,	1	
6	The Evolving Role of Pharmacoinformatics in Targeting Drug-Related Problems in Clinical Oncology Practice. 1541-1588		
5	Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China. <i>Iranian Journal of Public Health</i> , <b>2013</b> , 42, 472-9	0.7	5
4	Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e227958	10.4	3

- 3 Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study.  
**2022**, 17, e0274115 ○
- 2 DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. ○
- 1 Management guideline for the off-label use of medicine in China (2021). 1-16 ○